Back

BeyondSpring wins FDA Fast Track status for Plinabulin lung-cancer regimen

Verifying
  • FDA grants BeyondSpring Fast Track status for Plinabulin plus docetaxel in advanced non-squamous NSCLC.
  • DUBLIN-4 plans to enroll 442 patients, including approximately 221 in China.
  • BeyondSpring will retain Plinabulin rights outside Greater China after the subsidiary sale.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.